These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20664284)

  • 1. Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients.
    Kinouchi K; Ichihara A; Sakoda M; Kurauchi-Mito A; Murohashi-Bokuda K; Itoh H
    Kidney Blood Press Res; 2010; 33(4):304-12. PubMed ID: 20664284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan-diuretic.
    Kojima M; Ohashi M; Dohi Y; Kimura G
    J Hypertens; 2013 Jan; 31(1):186-91. PubMed ID: 23047595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
    Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
    Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential impact of angiotensin receptor blockers and calcium channel blockers on arterial stiffness.
    Andreadis EA; Sfakianakis ME; Tsourous GI; Georgiopoulos DX; Fragouli EG; Katsanou PM; Tavoularis EI; Skarlatou MG; Marakomichelakis GE; Ifanti GK; Diamantopoulos EJ
    Int Angiol; 2010 Jun; 29(3):266-72. PubMed ID: 20502415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study.
    Littlejohn TW; Majul CR; Olvera R; Seeber M; Kobe M; Guthrie R; Oigman W;
    Postgrad Med; 2009 Mar; 121(2):5-14. PubMed ID: 19332958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
    Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S;
    Hypertens Res; 2008 Apr; 31(4):657-64. PubMed ID: 18633177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
    Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
    Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.
    Weinbergová O; Metelka R; Vymetal J; Konecný K; Kosatíková Z
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Jul; 148(1):69-73. PubMed ID: 15523550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria.
    Fogari R; Derosa G; Zoppi A; Preti P; Lazzari P; Destro M; Fogari E; Rinaldi A; Mugellini A
    Am J Hypertens; 2007 Apr; 20(4):417-22. PubMed ID: 17386350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
    Ishimitsu T; Kobayashi T; Honda T; Takahashi M; Minami J; Ohta S; Inada H; Yoshii M; Ono H; Matsuoka H
    Hypertens Res; 2005 Apr; 28(4):351-9. PubMed ID: 16138566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate.
    Nakagawa N; Fujino T; Kabara M; Matsuki M; Chinda J; Kikuchi K; Hasebe N;
    Hypertens Res; 2011 Oct; 34(10):1121-6. PubMed ID: 21796123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of angiotensin receptor II blockade improves vascular function, urinary albumin excretion, and left ventricular hypertrophy in low-risk essential hypertensive patients receiving antihypertensive treatment with calcium channel blockers.
    Watanabe Y; Kikuchi T; Mitsuhashi T; Kimura H; Tsuchida Y; Otsuka K
    Clin Exp Hypertens; 2013; 35(2):87-94. PubMed ID: 22679900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan.
    Wago T; Yoshimoto T; Akaza I; Tsuchiya K; Izumiyama H; Doi M; Hirata Y
    Hypertens Res; 2010 Aug; 33(8):796-801. PubMed ID: 20555330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review: a single-pill combination of telmisartan plus amlodipine for the treatment of hypertension.
    Guthrie RM
    Postgrad Med; 2011 Nov; 123(6):58-65. PubMed ID: 22104454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
    White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
    Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
    Masuda S; Tamura K; Wakui H; Kanaoka T; Ohsawa M; Maeda A; Dejima T; Yanagi M; Azuma K; Umemura S
    Hypertens Res; 2009 Nov; 32(11):950-5. PubMed ID: 19713965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal and vascular protective effects of telmisartan in patients with essential hypertension.
    Morimoto S; Yano Y; Maki K; Sawada K
    Hypertens Res; 2006 Aug; 29(8):567-72. PubMed ID: 17137211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-albuminuric effects of the angiotensin AT1 receptor blocker telmisartan in hypertensive patients.
    Rodríguez-Pérez JC; García-Bello MA; Anabitarte-Prieto A; Companioni O; Nóvoa-Mogollón FJ; Suárez-Ortega S; Plaza-Toledano C; Rodríguez-Esparragón F
    Clin Exp Hypertens; 2011; 33(8):506-10. PubMed ID: 21958392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of AT1 receptor and beta1 receptor blocking on blood pressure, peripheral hemodynamic and lipid profile in statin-treated hypertensive hypercholesterolemic patients.
    Cicero AF; Veronesi M; Prandin MG; Di Gregori V; Ambrosioni E; Borghi C
    Fundam Clin Pharmacol; 2009 Oct; 23(5):583-8. PubMed ID: 19555395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.